Free Trial

Viatris (VTRS) Competitors

Viatris logo
$8.88 -0.39 (-4.21%)
Closing price 04:00 PM Eastern
Extended Trading
$8.94 +0.05 (+0.62%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VTRS vs. PFE, ARGX, ONC, BNTX, INSM, SMMT, TEVA, ITCI, GMAB, and MRNA

Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Pfizer (PFE), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and Moderna (MRNA). These companies are all part of the "medical" sector.

Viatris vs. Its Competitors

Viatris (NASDAQ:VTRS) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 5.4%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.0%. Viatris pays out -15.1% of its earnings in the form of a dividend. Pfizer pays out 124.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

79.9% of Viatris shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.1% of Viatris shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pfizer has a net margin of 12.62% compared to Viatris' net margin of -26.45%. Pfizer's return on equity of 20.33% beat Viatris' return on equity.

Company Net Margins Return on Equity Return on Assets
Viatris-26.45% 16.20% 7.01%
Pfizer 12.62%20.33%8.53%

In the previous week, Pfizer had 66 more articles in the media than Viatris. MarketBeat recorded 81 mentions for Pfizer and 15 mentions for Viatris. Viatris' average media sentiment score of 1.20 beat Pfizer's score of 0.67 indicating that Viatris is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viatris
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
8 Negative mention(s)
0 Very Negative mention(s)
Positive
Pfizer
52 Very Positive mention(s)
4 Positive mention(s)
18 Neutral mention(s)
4 Negative mention(s)
2 Very Negative mention(s)
Positive

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viatris$14.74B0.71-$634.20M-$3.17-2.80
Pfizer$63.63B2.19$8.03B$1.3817.72

Viatris presently has a consensus price target of $10.40, suggesting a potential upside of 17.12%. Pfizer has a consensus price target of $28.55, suggesting a potential upside of 16.72%. Given Viatris' higher possible upside, analysts plainly believe Viatris is more favorable than Pfizer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viatris
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80
Pfizer
1 Sell rating(s)
13 Hold rating(s)
5 Buy rating(s)
3 Strong Buy rating(s)
2.45

Viatris has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Summary

Pfizer beats Viatris on 14 of the 20 factors compared between the two stocks.

Get Viatris News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VTRS vs. The Competition

MetricViatrisMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$10.88B$6.78B$5.52B$9.41B
Dividend Yield5.18%2.87%3.80%4.04%
P/E Ratio-2.8026.7728.0419.84
Price / Sales0.7135.79429.5399.59
Price / Cash1.8226.7235.8457.94
Price / Book0.579.028.125.65
Net Income-$634.20M$233.10M$3.25B$258.00M
7 Day Performance-2.63%-0.15%0.97%2.09%
1 Month Performance1.25%1.22%7.36%11.13%
1 Year Performance-24.55%23.83%31.31%18.40%

Viatris Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VTRS
Viatris
3.2683 of 5 stars
$8.88
-4.2%
$10.40
+17.1%
-21.7%$10.88B$14.74B-2.8032,000Trending News
PFE
Pfizer
4.9618 of 5 stars
$25.36
-1.2%
$28.55
+12.6%
-18.1%$144.15B$62.46B18.3781,000Trending News
ARGX
argenex
4.4966 of 5 stars
$561.28
+0.2%
$728.06
+29.7%
+23.6%$34.35B$2.25B34.631,599Positive News
Analyst Revision
ONC
BeOne Medicines
2.5583 of 5 stars
$252.14
+0.7%
$320.67
+27.2%
N/A$27.63B$3.81B-67.7811,000Analyst Forecast
Gap Up
BNTX
BioNTech
1.4591 of 5 stars
$111.00
-1.7%
$137.91
+24.2%
+28.4%$26.68B$2.98B-32.656,772Analyst Forecast
INSM
Insmed
3.8659 of 5 stars
$101.89
+3.8%
$108.07
+6.1%
+37.9%$19.33B$381.03M-17.121,271Positive News
Analyst Forecast
Insider Trade
SMMT
Summit Therapeutics
2.886 of 5 stars
$25.40
+1.6%
$34.67
+36.5%
+196.8%$18.86BN/A-74.70110
TEVA
Teva Pharmaceutical Industries
4.1195 of 5 stars
$16.43
+0.2%
$24.71
+50.5%
-0.4%$18.84B$16.54B-14.2836,830
ITCI
Intra-Cellular Therapies
0.9225 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.9168 of 5 stars
$21.46
+0.3%
$37.80
+76.1%
-18.0%$13.77B$3.12B12.192,682Analyst Revision
MRNA
Moderna
4.2835 of 5 stars
$32.88
-2.3%
$46.61
+41.8%
-74.0%$12.72B$3.24B-3.775,800Trending News
Options Volume
Analyst Revision

Related Companies and Tools


This page (NASDAQ:VTRS) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners